Study Details

General Information

Envivo Schizophrenia Ext 017

A Multicenter 40-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy

Protocol
IdentifierEVP-6124-017
UIDeb735241-7f0d-45f2-b213-041656777769
StatusDone - Archived
Phase3
CategorySchizophrenia / Adult
Launch Year2012
NCT Number-
Created2012-10-05 16:35
Last Updated2012-10-05 16:35

Description

No description provided.

Comment

No comment.

Target Dates

NameDateRequired
Enrollment ClosedNo
Enrollment OpenNo
First Patient First VisitNo
Site Initiation Mtg.No
PI Meeting StartNo
PI Meeting EndNo
PI Meeting ArrivalNo
PI Meeting DepartureNo
Closeout Date2013-09-12No
Final PatientVisitNo
PreStudy Selection VisitNo
Target Date 12No
Target Date 13No
Target Date 14No

Leadership

RoleStaffLoginRequired
PrincipalMohaupt, StephenSMohauptNo
Recruiter-No
CoordinatorCalleros, JessicaJNCallerosNo
RegulatoryAguirre, SandraSAguirreNo

Custom Fields

No custom fields.

Sponsor & Organization

SponsorEnvivo Pharmaceuticals
DivisionEnvivo Pharmaceuticals
TeamEnvivo Pharmaceuticals
Managing SiteCatalina Research Institute, LLC
Organization

Contacts

IRB RefIRB ID No. INC1-12-350
CROInc Research, LLC
CRO Ref
Correspondence0

Opportunity

Probability0
Comment
Status ColorGainsboro
Currency-
Mayra Sibley

2 Hours

Hi there, I'm Jesse and you?
You

3 minutes

My name is Anne Clarc.
Mayra Sibley

40 seconds

Nice to meet you Anne.
How can i help you?